Notice
Recent Posts
Recent Comments
Link
| 일 | 월 | 화 | 수 | 목 | 금 | 토 |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | 31 |
Tags
- Mash
- Viking Therapeutics
- GPCR
- CAR-T
- glp-1 비만
- orforglipron
- danuglipron
- 노보노디스크
- Nash
- 바이오스터디
- tern-601
- 제약바이오
- Pegozafermin
- 비만치료제
- tirzepatide
- Semaglutide
- VKTX
- GLP-1치료제
- gsbr-1290
- Novo Nordisk
- Efruxifermin
- GLP-1 치료제
- GLP-1
- il-17 inhibitor
- CAR-T in autoimmune
- VK2735
- 경구용 glp-1
- 자가면역질환 치료제
- lilly
- ct-996
Archives
- Today
- Total
목록2024/10/27 (1)
제약바이오 츄롸이츄롸이!~
Viking Therapeutics (NASDAQ: VKTX) - 24년 3분기 실적발표 3Q24
https://ir.vikingtherapeutics.com/2024-10-23-Viking-Therapeutics-Reports-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateConference call scheduled for 4:30 p.m. ET today End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24 Phase 2 Study of Oral VK2735 in Obesity..
개별 스터디
2024. 10. 27. 18:00